|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...1415161718192021222324...6768» |
- bortezomib / Generic mfg., melphalan / Generic mfg.
Enrollment closed, Enrollment change: Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 11, 2016
P1/2, N=11, Active, not recruiting, Sponsor: Mayo Clinic
Suspended --> Active, not recruiting | N=69 --> 11
- dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Enrollment closed, Trial primary completion date: Lenalidomide (Revlimid (clinicaltrials.gov) - Feb 11, 2016
P2, N=67, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Suspended --> Active, not recruiting | N=69 --> 11 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017
- tabalumab (LY2127399) / Eli Lilly
Trial completion, Combination therapy: Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma (clinicaltrials.gov) - Feb 10, 2016
P1, N=10, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- Alhemo (concizumab) / Novo Nordisk
Trial primary completion date: Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (clinicaltrials.gov) - Feb 10, 2016
P1, N=45, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Trial primary completion date: Jul 2017 --> Jan 2017
- bortezomib / Generic mfg., lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma (clinicaltrials.gov) - Feb 10, 2016
P1, N=12, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Jul 2017 --> Jan 2017 Trial primary completion date: Jan 2016 --> Sep 2016
- decitabine / Generic mfg.
Trial completion: Decitabine for High-Risk Sickle Cell Disease (clinicaltrials.gov) - Feb 9, 2016
P2, N=10, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Jan 2016 --> Sep 2016 Suspended --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium (clinicaltrials.gov) - Feb 8, 2016
P2, N=33, Completed, Sponsor: Amgen
Suspended --> Completed Trial primary completion date: Aug 2013 --> Sep 2012
- | fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg., cyclosporine / Generic mfg.
Trial completion: MINI HEME: Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders (clinicaltrials.gov) - Feb 8, 2016
P2, N=25, Completed, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Aug 2013 --> Sep 2012 Active, not recruiting --> Completed
- lenalidomide / Generic mfg., cyclophosphamide / Generic mfg.
Trial initiation date: Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM) (clinicaltrials.gov) - Feb 8, 2016
P2, N=80, Recruiting, Sponsor: Fondazione Neoplasie Sangue Onlus
Active, not recruiting --> Completed Initiation date: Apr 2012 --> Mar 2013
- Xofigo (radium Ra-223 dichloride) / Bayer
Enrollment change, Trial initiation date, Trial withdrawal, Combination therapy: Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma (clinicaltrials.gov) - Feb 8, 2016
P1/2, N=0, Withdrawn, Sponsor: Bayer
Initiation date: Apr 2012 --> Mar 2013 N=226 --> 0 | Initiation date: Mar 2016 --> Jun 2016 | Not yet recruiting --> Withdrawn
- | carfilzomib / Generic mfg.
Clinical: Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function (clinicaltrials.gov) - Feb 5, 2016
P2, N=50, Completed, Sponsor: Onyx Therapeutics, Inc.
N=226 --> 0 | Initiation date: Mar 2016 --> Jun 2016 | Not yet recruiting --> Withdrawn N=36 --> 50
- ||| lenalidomide / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: PrE1003: Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction (clinicaltrials.gov) - Feb 5, 2016
P1/2, N=62, Active, not recruiting, Sponsor: PrECOG, LLC.
N=36 --> 50 Recruiting --> Active, not recruiting | N=111 --> 62 | Trial primary completion date: Dec 2017 --> Dec 2018
- Biomarker, Trial primary completion date: Correlative Biomarker Study in Patients With Myeloproliferative Disorders (clinicaltrials.gov) - Feb 3, 2016
P=N/A, N=860, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Recruiting --> Active, not recruiting | N=111 --> 62 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2015 --> Jun 2019
- Trial primary completion date: Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (clinicaltrials.gov) - Feb 2, 2016
P=N/A, N=400, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Dec 2015 --> Jun 2019 Trial primary completion date: Aug 2016 --> Jan 2017
- melphalan / Generic mfg.
New P2 trial: Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation (clinicaltrials.gov) - Feb 1, 2016
P2, N=24, Not yet recruiting, Sponsor: Medical College of Wisconsin
- | Kcentra (plasma-derived prothrombin complex concentrate) / CSL Behring
Enrollment closed: Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects (clinicaltrials.gov) - Jan 28, 2016
P3, N=11, Active, not recruiting, Sponsor: CSL Behring
Trial primary completion date: Aug 2016 --> Jan 2017 Recruiting --> Active, not recruiting
- Enrollment closed: Single Incision Versus Standard Laparoscopic Splenectomy (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=30, Active, not recruiting, Sponsor: Children's Mercy Hospital Kansas City
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ulocuplumab (BMS-936564) / BMS
New trial: Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=0, Available, Sponsor: Dana-Farber Cancer Institute
- Trial completion: Impact of Vasculitis on Employment and Income (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=426, Completed, Sponsor: University of South Florida
Recruiting --> Active, not recruiting Recruiting --> Completed
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) - Jan 28, 2016
P1/2, N=10, Recruiting, Sponsor: Adaptimmune
Recruiting --> Completed Trial primary completion date: Apr 2016 --> Apr 2017
- telaglenastat (CB-839) / Calithera
Metastases: Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors (clinicaltrials.gov) - Jan 28, 2016
P1, N=25, Recruiting, Sponsor: Calithera Biosciences, Inc
Trial primary completion date: Apr 2016 --> Apr 2017 N=65 --> 25 | Trial primary completion date: Dec 2015 --> Mar 2016
- BI 655064 / AbbVie, Boehringer Ingelheim
Enrollment change: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - Jan 28, 2016
P1, N=6, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=65 --> 25 | Trial primary completion date: Dec 2015 --> Mar 2016 N=10 --> 6
- | carfilzomib / Generic mfg.
Clinical: Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 28, 2016
P2, N=44, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
N=10 --> 6 Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Jan 2016
- rVIIa-FP (CSL689) / CSL Behring
Trial primary completion date: Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency (clinicaltrials.gov) - Jan 28, 2016
P1, N=16, Recruiting, Sponsor: CSL Behring
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Jan 2016 Trial primary completion date: Dec 2015 --> Jul 2016
- Promacta (eltrombopag) / Novartis
Trial completion, Enrollment change, Trial primary completion date: Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 26, 2016
P2, N=1, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2015 --> Jul 2016 Active, not recruiting --> Completed | N=24 --> 1 | Trial primary completion date: Sep 2015 --> Jan 2016
- CYAD-01 / Celdara Medical, Celyad Oncology
Trial primary completion date, Metastases: Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (clinicaltrials.gov) - Jan 26, 2016
P1, N=21, Recruiting, Sponsor: Celdara Medical, LLC
Active, not recruiting --> Completed | N=24 --> 1 | Trial primary completion date: Sep 2015 --> Jan 2016 Trial primary completion date: Mar 2019 --> Mar 2017
- New trial: Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders (clinicaltrials.gov) - Jan 26, 2016
P=N/A, N=300, Not yet recruiting, Sponsor: Shandong University
- bortezomib / Generic mfg., lenalidomide / Generic mfg.
Trial completion, Combination therapy: Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 25, 2016
P1, N=58, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Mar 2019 --> Mar 2017 Active, not recruiting --> Completed
- || DCR-MYC / Novo Nordisk
Trial primary completion date, Metastases: Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma (clinicaltrials.gov) - Jan 21, 2016
P1, N=74, Recruiting, Sponsor: Dicerna Pharmaceuticals, Inc.
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- Enrollment closed, Enrollment change: Exploratory Pilot Study of Physical Activity Monitoring in Adult Patients With Haemophilia A by Means of Accelerometry (clinicaltrials.gov) - Jan 21, 2016
P=N/A, N=28, Active, not recruiting, Sponsor: University of Valencia
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting | N=20 --> 28
- Kovaltry (octocog alfa) / Bayer, CSL Behring
Trial completion: Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate (clinicaltrials.gov) - Jan 20, 2016
P1, N=8, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=20 --> 28 Active, not recruiting --> Completed
- melphalan / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: HD Melphalan and SCT in Patients With IGDD or LCDD (clinicaltrials.gov) - Jan 19, 2016
P2, N=5, Terminated, Sponsor: Boston Medical Center
Active, not recruiting --> Completed N=30 --> 5 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jan 2016; Poor accrual
- bortezomib / Generic mfg., melphalan / Generic mfg.
Trial completion: Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis (clinicaltrials.gov) - Jan 19, 2016
P2, N=10, Completed, Sponsor: Boston Medical Center
N=30 --> 5 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jan 2016; Poor accrual Active, not recruiting --> Completed
- |||| lenalidomide / Generic mfg.
Trial completion, Immunomodulating: CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (clinicaltrials.gov) - Jan 19, 2016
P2, N=82, Completed, Sponsor: Vaishali Sanchorawala
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | GO-203-2c / Genus Oncology
New P1 trial, Combination therapy: GO-203-2C + Bortezomib For Relapsed Or Refractory MM (clinicaltrials.gov) - Jan 19, 2016
P1, N=28, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- Trial primary completion date: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Jan 18, 2016
P=N/A, N=80, Recruiting, Sponsor: Michael A. Thompson, MD, PhD
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- TevaGrastim (filgrastim biosimilar) / Nippon Kayaku, Teva, Mozobil (plerixafor) / Sanofi
Trial primary completion date, Combination therapy, Head-to-Head: Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 18, 2016
P2, N=100, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- carfilzomib / Generic mfg.
Clinical: CARAMEL 2: Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (clinicaltrials.gov) - Jan 17, 2016
P2, N=43, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: May 2015 --> May 2016
- |||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Trial primary completion date: ARETA: Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (clinicaltrials.gov) - Jan 17, 2016
P3, N=280, Active, not recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: Aug 2015 --> Mar 2016
- Quadramet (samarium 153 lexidronam) / Jazz
Trial primary completion date: Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain (clinicaltrials.gov) - Jan 17, 2016
P1/2, N=39, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Aug 2015 --> Mar 2016 Trial primary completion date: Sep 2015 --> May 2016
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Jan 17, 2016
P1, N=42, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Sep 2015 --> May 2016 Trial primary completion date: Sep 2015 --> May 2016
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg., bendamustine / Generic mfg.
Trial completion, Combination therapy: Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 16, 2016
P1, N=29, Completed, Sponsor: Robert Redner, MD
Trial primary completion date: Sep 2015 --> May 2016 Active, not recruiting --> Completed
- bortezomib / Generic mfg.
Enrollment closed, Preclinical: Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro (clinicaltrials.gov) - Jan 16, 2016
P=N/A, N=20, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Enrollment closed, Enrollment change: Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jan 15, 2016
P2, N=17, Active, not recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=35 --> 17
- morphine sulphate / Generic mfg.
Enrollment open: Colloid Pre-Loading on D-Dimer During Cesarean Section Under Spinal Anesthesia (clinicaltrials.gov) - Jan 15, 2016
P2, N=60, Recruiting, Sponsor: Assiut University
Recruiting --> Active, not recruiting | N=35 --> 17 Not yet recruiting --> Recruiting
- Enrollment open: Coagulation Disorders After Aneurysmatic Subarachnoid Haemorrhage (clinicaltrials.gov) - Jan 15, 2016
P=N/A, N=32, Recruiting, Sponsor: Tampere University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Enrollment open, Patient reported outcomes: ECHO: Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (clinicaltrials.gov) - Jan 15, 2016
P=N/A, N=2000, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Trial completion, Enrollment change: Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) (clinicaltrials.gov) - Jan 15, 2016
P=N/A, N=449, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Enrolling by invitation --> Completed | N=300 --> 449
- ||||| Tavalisse (fostamatinib) / Rigel
Enrollment closed: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Jan 15, 2016
P3, N=75, Active, not recruiting, Sponsor: Rigel Pharmaceuticals
Enrolling by invitation --> Completed | N=300 --> 449 Recruiting --> Active, not recruiting
- | Empliciti (elotuzumab) / AbbVie, BMS
New P1 trial, Combination therapy: Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma (clinicaltrials.gov) - Jan 14, 2016
P1, N=15, Recruiting, Sponsor: Hearn Jay Cho